Literature DB >> 7608899

The serotonin 5-HT4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists.

K H Buchheit1, R Gamse, R Giger, D Hoyer, F Klein, E Klöppner, H J Pfannkuche, H Mattes.   

Abstract

A number of substituted indole carbazimidamides were prepared and evaluated as 5-HT4 receptor agonists by using the isolated field-stimulated guinea pig ileum preparation. Their selectivity for the 5-HT4 receptor was established by examining their affinity for other 5-HT receptors using radioligand-binding techniques. Several selective and highly potent full as well as partial agonists emerged from this study. For example, 1b,d were found to be the most potent, full 5-HT4 receptor agonist described so far (EC50 = 0.5 and 0.8 nM, respectively), being 6 and 4 times more potent than serotonin itself. On the other hand, 5b and 1h appeared as partial 5-HT4 receptor agonists in the nonstimulated guinea pig ileum preparation with potencies, evaluated against serotonin action, respectively similar (5b, Ki = 12 nM) to and 300-fold higher (1h, Ki = 0.04 nM) than serotonin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7608899     DOI: 10.1021/jm00013a010

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.

Authors:  S Appel-Dingemanse; M O Lemarechal; A Kumle; M Hubert; E Legangneux
Journal:  Br J Clin Pharmacol       Date:  1999-05       Impact factor: 4.335

Review 2.  Pharmacology of serotonin: what a clinician should know.

Authors:  F De Ponti
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

Review 3.  Tegaserod.

Authors:  L J Scott; C M Perry
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 4.  Role of serotonin in Alzheimer's disease: a new therapeutic target?

Authors:  Werner J Geldenhuys; Cornelis J Van der Schyf
Journal:  CNS Drugs       Date:  2011-09-01       Impact factor: 5.749

5.  The inability of tegaserod to affect platelet aggregation and coronary artery tone at supratherapeutic concentrations.

Authors:  Deborah L Higgins; Mike P Ero; Michelle Loeb; Kathryn Kersey; Alan Hopkins; David T Beattie
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-08       Impact factor: 3.000

6.  Indole-Containing Amidinohydrazones as Nonpeptide, Dual RXFP3/4 Agonists: Synthesis, Structure-Activity Relationship, and Molecular Modeling Studies.

Authors:  Dongliang Guan; Md Toufiqur Rahman; Elaine A Gay; Vineetha Vasukuttan; Kelly M Mathews; Ann M Decker; Alexander H Williams; Chang-Guo Zhan; Chunyang Jin
Journal:  J Med Chem       Date:  2021-12-02       Impact factor: 7.446

Review 7.  Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.

Authors:  Antona J Wagstaff; James E Frampton; Katherine F Croom
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo.

Authors:  D T Beattie; J A M Smith; D Marquess; R G Vickery; S R Armstrong; T Pulido-Rios; J L McCullough; C Sandlund; C Richardson; N Mai; P P A Humphrey
Journal:  Br J Pharmacol       Date:  2004-10-04       Impact factor: 8.739

9.  Structure-activity relationships of lipopolysaccharide sequestration in guanylhydrazone-bearing lipopolyamines.

Authors:  Wenyan Wu; Diptesh Sil; Michal L Szostak; Subbalakshmi S Malladi; Hemamali J Warshakoon; Matthew R Kimbrell; Jens R Cromer; Sunil A David
Journal:  Bioorg Med Chem       Date:  2008-11-24       Impact factor: 3.641

10.  The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties.

Authors:  David T Beattie; Scott R Armstrong; Ross G Vickery; Pamela R Tsuruda; Christina B Campbell; Carrie Richardson; Julia L McCullough; Oranee Daniels; Kathryn Kersey; Yu-Ping Li; Karl H S Kim
Journal:  Front Pharmacol       Date:  2011-05-30       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.